Disclaimer: This website does not include all the adverse drug reactions (ADRs) that may occur in practice. At present, the database only contains ADRs affecting 5 system organ classes. Thus, a search for a particular ADR may not yield any results. A negative search result should not be interpreted to mean that no drugs cause that particular ADR. The data was sourced from Summary of Product Characteristics (SPCs) of Medicinal products present in Malta. Thus, other drugs (available outside Malta), besides those enlisted may also be responsible for a particular ADR. This work was carried out by Stephanie Bezzina under the supervision of Dr. Maurice Zarb Adami as part of her submission for the degree of Master of Pharmacy.
Several thousands of deaths are reported each year as a result of Adverse Drug Reactions and several more patients suffer their negative effects. It has been calculated that ADRs are the 4th to 6th largest cause for mortality in the USA (Lazarou et al, 1998). The percentage of hospital admissions due to adverse drug reactions averages 10% in most developed countries (Moore et al, 1998; Griffin, 1998).
The sole fact that the patient knows that ADRs can occur is enough to discourage the patient let alone if the individual should actually experience such a reaction during therapy. In order to decrease the occurrence of ADRs and improve compliance, the health care professional (HCP) must assess the benefits and harms of the drug against reliable evidence, and must also take into account other predisposing factors that may lead to drug toxicity. In the event that an ADR should occur, the HCP should immediately be able to identify the cause and act to oppose the harmful effect. The ADR database is designed to aid the HCP in this task.
Griffin GP. The evaluation of human medicines control from a national to an international perspective. Ad Drug React Toxico Rev 1998; 17(1): 19-50. Lazarou J, Pomeranz BH, Corey PN et al., 1998. Incidence of ADR in hospitalized patients: a meta-analysis of prospective studies. JAMA, 1998; 279 (15): 1000-1005. Moore N, Lecomtre D, Noblet C, Mabille M, et al. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998; 45(3): 301-308.